Tuesday - July 8, 2025
SAN DIEGO / Apr 03, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability initiatives that are aligned with Dexcom’s core values and business strategy.
“We are always working to advance the interests of our stakeholders, including our global customer base, employees and their families, caregivers, our communities, and our shareholders,” said Kevin Sayer, chairman, president and CEO of Dexcom. “We see an inherent connection between sustainability and strategy and look forward to continuing to drive advances in global health through access to Dexcom CGM technology.”
Dexcom’s sustainability initiatives are integrated as foundational elements of the company’s core values and business strategy. The sustainability report is once again framed according to the company’s four core values: Listen, Think Big, Be Dependable, and Serve with Integrity.
Highlights from this year’s report include:
Dexcom’s annual Sustainability Report can be found on the company’s investor relations site at investors.dexcom.com. All data in the report reflects fiscal year 2023, unless noted otherwise.
About DexCom, Inc.
DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
Last Trade: | US$82.94 |
Daily Change: | 0.01 0.01 |
Daily Volume: | 2,592,489 |
Market Cap: | US$32.400B |
May 01, 2025 April 10, 2025 April 01, 2025 March 25, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load